Literature DB >> 1902817

Clozapine's cost-benefits.

.   

Abstract

Entities:  

Mesh：

Substances：

Year:  1991        PMID： 1902817

Source DB:  PubMed          Journal:  Hosp Community Psychiatry        ISSN： 0022-1597


× No keyword cloud information.
  4 in total

Review 1.  Methodological issues in economic assessments of new therapies. The case of colony-stimulating factors.

Authors:  M Drummond; J Menzin; G Oster
Journal:  Pharmacoeconomics       Date:  1994       Impact factor: 4.981

2.  The cost-effectiveness of clozapine: a survey of the literature.

Authors:  S Morris; T Hogan; A McGuire
Journal:  Clin Drug Investig       Date:  1998       Impact factor: 2.859

3.  Clozapine: an appraisal of its pharmacoeconomic benefits in the treatment of schizophrenia.

Authors:  A Fitton; P Benfield
Journal:  Pharmacoeconomics       Date:  1993-08       Impact factor: 4.981

4.  Clinical and economic outcomes of olanzapine compared with haloperidol for schizophrenia. Results from a randomised clinical trial.

Authors:  S H Hamilton; D A Revicki; E T Edgell; L A Genduso; G Tollefson
Journal:  Pharmacoeconomics       Date:  1999-05       Impact factor: 4.981
  4 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.